SE446530B - Nya derivat av 6-metoxi-2-acetylnaftalenoxim, vilka derivat har analgetiska, antipyretiska och anti-inflammatoriska egenskaper - Google Patents
Nya derivat av 6-metoxi-2-acetylnaftalenoxim, vilka derivat har analgetiska, antipyretiska och anti-inflammatoriska egenskaperInfo
- Publication number
- SE446530B SE446530B SE7906509A SE7906509A SE446530B SE 446530 B SE446530 B SE 446530B SE 7906509 A SE7906509 A SE 7906509A SE 7906509 A SE7906509 A SE 7906509A SE 446530 B SE446530 B SE 446530B
- Authority
- SE
- Sweden
- Prior art keywords
- methoxy
- derivatives
- oxime
- acetylnaphthalene
- derivative according
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title description 8
- 230000003110 anti-inflammatory effect Effects 0.000 title description 3
- 230000001754 anti-pyretic effect Effects 0.000 title description 2
- 239000002221 antipyretic Substances 0.000 title description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 150000002923 oximes Chemical class 0.000 claims description 9
- BJKZQNPIHGBLIV-UHFFFAOYSA-N 2-[1-(6-methoxynaphthalen-2-yl)ethylideneamino]oxy-n,n-dimethylethanamine Chemical compound C1=C(C(C)=NOCCN(C)C)C=CC2=CC(OC)=CC=C21 BJKZQNPIHGBLIV-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- SAJXURINXUVSAT-UHFFFAOYSA-N n,n-diethyl-2-[1-(6-methoxynaphthalen-2-yl)ethylideneamino]oxyethanamine Chemical group C1=C(OC)C=CC2=CC(C(C)=NOCCN(CC)CC)=CC=C21 SAJXURINXUVSAT-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- FKUMAWUBPURONA-UHFFFAOYSA-N n-[1-(6-methoxynaphthalen-2-yl)ethylidene]hydroxylamine Chemical class C1=C(C(C)=NO)C=CC2=CC(OC)=CC=C21 FKUMAWUBPURONA-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000047 product Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical class NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 2
- -1 6-methoxy-2-acetylnaphthac-O- (2-dimethylaminoethyl) oxime Chemical class 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 240000008213 Brosimum alicastrum Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- ZEHGKSPCAMLJDC-UHFFFAOYSA-M acetylcholine bromide Chemical compound [Br-].CC(=O)OCC[N+](C)(C)C ZEHGKSPCAMLJDC-UHFFFAOYSA-M 0.000 description 1
- 229940080018 acetylcholine injection Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004177 diethyl group Chemical class [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000005828 ramon Nutrition 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7822836A FR2432506A1 (fr) | 1978-08-02 | 1978-08-02 | Nouveaux derives de 6-methoxy-2-acetylnaphtalene oxime, leur preparation et leur application en tant que medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
SE7906509L SE7906509L (sv) | 1980-02-03 |
SE446530B true SE446530B (sv) | 1986-09-22 |
Family
ID=9211492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE7906509A SE446530B (sv) | 1978-08-02 | 1979-08-01 | Nya derivat av 6-metoxi-2-acetylnaftalenoxim, vilka derivat har analgetiska, antipyretiska och anti-inflammatoriska egenskaper |
Country Status (25)
Country | Link |
---|---|
US (1) | US4267334A (fr) |
JP (1) | JPS5555155A (fr) |
AR (1) | AR221502A1 (fr) |
AT (1) | AT367744B (fr) |
BE (1) | BE878019A (fr) |
BG (1) | BG36198A3 (fr) |
CA (1) | CA1128519A (fr) |
CH (1) | CH641773A5 (fr) |
CS (1) | CS215016B2 (fr) |
DD (1) | DD145266A5 (fr) |
DE (1) | DE2931319A1 (fr) |
EG (1) | EG14368A (fr) |
ES (1) | ES481855A1 (fr) |
FI (1) | FI70012C (fr) |
FR (1) | FR2432506A1 (fr) |
GB (1) | GB2045743B (fr) |
GR (1) | GR69826B (fr) |
IL (1) | IL57931A (fr) |
NL (1) | NL7905939A (fr) |
PL (1) | PL116462B1 (fr) |
PT (1) | PT70005A (fr) |
RO (1) | RO77339A (fr) |
SE (1) | SE446530B (fr) |
SU (1) | SU784763A3 (fr) |
YU (1) | YU41874B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58156006U (ja) * | 1982-04-13 | 1983-10-18 | 日本電気ホームエレクトロニクス株式会社 | 車輌室内換気装置 |
JPS61192912U (fr) * | 1985-05-25 | 1986-12-01 | ||
JPH0525285Y2 (fr) * | 1987-01-12 | 1993-06-25 | ||
JPS63173814U (fr) * | 1987-05-02 | 1988-11-11 | ||
US7294719B2 (en) * | 2004-10-26 | 2007-11-13 | Sigma-Aldrich Co. | Synthesis of amino acid, N-carboxyanhydrides |
GB2435830A (en) * | 2006-03-09 | 2007-09-12 | Del Dr Esteve S A Spain Lab | Oxime ether compounds for the treatment of conditions associated with food uptake |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963778A (en) * | 1965-11-10 | 1976-06-15 | Bayer Aktiengesellschaft | Basic oximes and their preparation |
US3937841A (en) * | 1967-04-05 | 1976-02-10 | U.S. Philips Corporation | Treatment of depression |
-
1978
- 1978-08-02 FR FR7822836A patent/FR2432506A1/fr active Granted
-
1979
- 1979-06-06 ES ES481855A patent/ES481855A1/es not_active Expired
- 1979-07-20 US US06/059,249 patent/US4267334A/en not_active Expired - Lifetime
- 1979-07-26 YU YU1821/79A patent/YU41874B/xx unknown
- 1979-07-30 DD DD79214687A patent/DD145266A5/de not_active IP Right Cessation
- 1979-07-31 CH CH705179A patent/CH641773A5/fr not_active IP Right Cessation
- 1979-07-31 PT PT70005A patent/PT70005A/fr unknown
- 1979-07-31 GR GR59743A patent/GR69826B/el unknown
- 1979-07-31 IL IL57931A patent/IL57931A/xx not_active IP Right Cessation
- 1979-08-01 BG BG044522A patent/BG36198A3/xx not_active Expired
- 1979-08-01 RO RO7998336A patent/RO77339A/fr unknown
- 1979-08-01 JP JP9860079A patent/JPS5555155A/ja active Granted
- 1979-08-01 BE BE0/196559A patent/BE878019A/fr not_active IP Right Cessation
- 1979-08-01 CS CS795313A patent/CS215016B2/cs unknown
- 1979-08-01 CA CA333,015A patent/CA1128519A/fr not_active Expired
- 1979-08-01 PL PL1979217508A patent/PL116462B1/pl unknown
- 1979-08-01 NL NL7905939A patent/NL7905939A/nl not_active Application Discontinuation
- 1979-08-01 EG EG466/79A patent/EG14368A/xx active
- 1979-08-01 AT AT0528779A patent/AT367744B/de not_active IP Right Cessation
- 1979-08-01 DE DE19792931319 patent/DE2931319A1/de not_active Ceased
- 1979-08-01 SE SE7906509A patent/SE446530B/sv not_active IP Right Cessation
- 1979-08-02 SU SU792792753A patent/SU784763A3/ru active
- 1979-08-02 GB GB7926940A patent/GB2045743B/en not_active Expired
- 1979-08-02 AR AR277580A patent/AR221502A1/es active
- 1979-08-02 FI FI792414A patent/FI70012C/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
FR2432506A1 (fr) | 1980-02-29 |
BG36198A3 (en) | 1984-09-14 |
FR2432506B1 (fr) | 1981-07-24 |
IL57931A (en) | 1982-08-31 |
JPS5555155A (en) | 1980-04-22 |
SU784763A3 (ru) | 1980-11-30 |
EG14368A (en) | 1984-09-30 |
GR69826B (fr) | 1982-07-13 |
AT367744B (de) | 1982-07-26 |
CS215016B2 (en) | 1982-06-25 |
FI792414A (fi) | 1980-02-03 |
AR221502A1 (es) | 1981-02-13 |
SE7906509L (sv) | 1980-02-03 |
ATA528779A (de) | 1981-12-15 |
NL7905939A (nl) | 1980-02-05 |
ES481855A1 (es) | 1980-02-16 |
YU41874B (en) | 1988-02-29 |
BE878019A (fr) | 1980-02-01 |
PL217508A1 (fr) | 1980-03-24 |
IL57931A0 (en) | 1979-11-30 |
CA1128519A (fr) | 1982-07-27 |
FI70012B (fi) | 1986-01-31 |
GB2045743A (en) | 1980-11-05 |
US4267334A (en) | 1981-05-12 |
CH641773A5 (fr) | 1984-03-15 |
YU182179A (en) | 1983-04-30 |
JPS5748107B2 (fr) | 1982-10-14 |
GB2045743B (en) | 1982-09-02 |
RO77339A (fr) | 1981-08-17 |
FI70012C (fi) | 1986-09-12 |
DD145266A5 (de) | 1980-12-03 |
PL116462B1 (en) | 1981-06-30 |
DE2931319A1 (de) | 1980-02-14 |
PT70005A (fr) | 1979-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH672127A5 (fr) | ||
US4194045A (en) | 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds | |
HU201550B (en) | Process for producing 1,8-naphthyridine derivatives with twin ionic structure and pharmaceutical compositions comprising same | |
DE68906200T2 (de) | Kondensierte pyrazol-3-oxo-propannitril-derivate und verfahren zu deren herstellung. | |
DD263772A5 (de) | Verfahren zur herstellung neuer 1h, 3h-pyrrolo[1,2-c]thiazolderivate | |
SE446530B (sv) | Nya derivat av 6-metoxi-2-acetylnaftalenoxim, vilka derivat har analgetiska, antipyretiska och anti-inflammatoriska egenskaper | |
US4499286A (en) | Derivatives of thienylacetic acid amides and their pharmaceutically acceptable acid salts and a process for the preparation thereof | |
DE1949813B2 (de) | 3-(4-PyrWyl)-4-(2-hydroxyphenyl)-5-alkyl-pyrazole | |
US4103016A (en) | Antiinflammatory imidazothiazoles and thiazolopyrimidines | |
US4478838A (en) | 1-(3,4,5-Trimethoxycinnamoyl)-4-alkylaminocarbonylethyl piperazines | |
US3557135A (en) | 2-beta-hydroxy ethylamino-4-5-diphenyl-oxazole | |
NO883263L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater. | |
CA1310648C (fr) | Derives condenses de la pyrazole et procede pour leur preparation | |
CA1278572C (fr) | Compose ameliorant la circulation cerebrale et le metabolisme | |
SE446865B (sv) | Nya derivat av 1,3-bensoxazin-2,4-dion, forfarande for framstellning derav samt farmaceutiska kompositioner | |
JPS596851B2 (ja) | ピペリジン誘導体 | |
DE69018741T2 (de) | Konjugierte gamma-Hydroxybutenolid-Derivate und sie als aktiver Wirkstoff enthaltende Mittel gegen Magengeschwüre. | |
US3896143A (en) | Substituted pyrazolyl phenylacetic acid derivatives | |
US4309426A (en) | Muscle-relaxant 1,3,4-thiadiazin-2-amines | |
US4153702A (en) | Basically alkylated dithiosalicyclic acid amides and their use as medicaments | |
US3408445A (en) | Treatment of inflammation with 1-methyl - 3 - benzoyl - 4 - hydroxy - 4-phenylpiperidine and halo derivatives thereof | |
EP0573548B1 (fr) | Agents neuroprotecteurs | |
US4180577A (en) | Furo[2, 3d]pyrimidine derivatives and anti-ulcer containing the same | |
US4035497A (en) | Butanoic and butenoic acid morpholides | |
US4224334A (en) | Antiinflammatory imidazothiazoles and thiazolopyrimidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NAL | Patent in force |
Ref document number: 7906509-0 Format of ref document f/p: F |
|
NUG | Patent has lapsed |
Ref document number: 7906509-0 Format of ref document f/p: F |